Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Johann S. De Bono, Cora N. Sternberg, Bertrand F. TOMBAL, Daniel Castellano, Christian Wülfing, Michail Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Asgerour Sverrisdottir, Christine Theodore, Susan Feyerabend, Carole Helissey, Pascaline Picard, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Ronald De Wit
Institutions: Université Paris-Sud, Institut Gustave Roussy, Medical University of Vienna, Institut Jean Godinot, Royal Marsden NHS Foundation Trust, Weill Cornell Medicine, UCLouvain, Hospital Universitario 12 De Octubre, Asklepios Klinik Altona, National and Kapodistrian University of Athens, Alexandra Hospital, Vall d'Hebron Hospital Universitari, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, University Hospital Olomouc, National University Hospital of Iceland, Hôpital Foch, Hôpital d'Instruction des Armées Bégin, Sanofi (France), Erasmus MC
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3007505210